|
|
Post by sportsrancho on Mar 9, 2017 20:50:23 GMT -5
|
|
|
|
Post by sportsrancho on Mar 9, 2017 21:02:00 GMT -5
|
|
|
|
Post by slugworth008 on Mar 9, 2017 21:05:57 GMT -5
I just listened to about half of it - Very nice. Thanks for posting  |
|
|
|
Post by sportsrancho on Mar 9, 2017 21:21:12 GMT -5
I just listened to about half of it - Very nice. Thanks for posting I've never heard such detailed dosing info. About how Mike feels about the people on Afrezza that have touched his life. Afrezza is here to stay:-) |
|
|
|
Post by kc on Mar 9, 2017 21:59:09 GMT -5
Great interview but they use a crappy old picture. I sent a message to Mike to see if they could get that changed. Not his fault but they should send publications new current Technosphe photos. |
|
|
|
Post by careful2invest on Mar 9, 2017 22:16:14 GMT -5
I just listened to about half of it - Very nice. Thanks for posting Nice conversation, and any exposure is a positive thing, but I naturally critique what MNKD does, so here goes... I am curious as to why Mike did not mention that MNKD is working in conjunction with the JDRF for pediatric use, as well as the bold and positive comment of the head of the JDRF (an actual user of AFREZZA) of how AFREZZA has changed his life. That is one powerful endorsement that should be expressed for multiple reasons. Or that AFREZZA is the only treatment for Diabetes that actually mimics the function of a healthy human pancreas, etc...pk profile, etc. Or about the lable to try to obtain ULTRA RAPID ACTING clasification, and the progress of that etc... Mike is clearly a very intelligent man, and made many positive points, and I am not implying that he did a bad job in this interview, but IMHO, what we as investors and MNKD needs as well to turn this ship around is an enthusiastic front man/woman to conduct interviews such as this. Exhausting and explaining every atribute of AFREZZA. Maybe even stating goals of the marketing plan, goals for the patient, etc, or the plans for international launch (that is, if one exists) with enthusiasm. I even find myself being extremely enthusiastic when talking about AFREZZA to others. My kids are actually tired of hearing me tell people about it. And it is not only that I am so very heavily invested, AFREZZA is a revolutionary game changer, life changer, for Diabetics! That's why I invested so heavily to begin with! Bottom line is MNKD needs to do more in promotion of AFREZZA. Let's hope that they are able to pull it off! But this was a good interview nonetheless. Thanks for posting it Sports. GLTA! |
|
|
|
Post by avi8torslc on Mar 10, 2017 16:15:43 GMT -5
Nice. "Inhalable insulin becoming more mainstream"............when?
|
|
|
|
Post by dreamboatcruise on Mar 10, 2017 16:25:36 GMT -5
Nice. "Inhalable insulin becoming more mainstream"............when? Mainstream... sidelined... those two words are easily confused. Words are no longer meant to be taken literally. It's 2017. |
|
|
|
Post by careful2invest on Mar 10, 2017 19:03:11 GMT -5
Nice. "Inhalable insulin becoming more mainstream"............when? Mainstream... sidelined... those two words are easily confused. Words are no longer meant to be taken literally. It's 2017. Could be another case of alternative facts... |
|
|
|
Post by MnkdWASmyRtrmntPlan on Mar 10, 2017 20:54:32 GMT -5
Good interview. Thanks for posting that, Sports.
In case you don't have a spare 30 minutes to listen to that, here are the highlights that stood out to me:
Mike thinks that over the next 12 to 18 months, people’s lives are going to get a lot better (less finger pricks, etc.). You will see more inhalable insulin – it will be more mainstream, oral tablets, once-daily injections, once-weekly injections. People’s lives with diabetes will start to get a lot better.
Shows like this help us get the word out that Afrezza is still available. It's not going anywhere. If you were on Afrezza, it's easy to get back on it.
Medicare coverage isn’t as strong as Commercial. Commercially, we have a little over 70% coverage. With Medicare, sometimes you might need a minor prior-authorization, which isn’t a big deal. We usually get those approved in a day or two. It takes about 18 months to get a medicare plan added. More than half medicare plans aren’t covered, but as we get to 2018 that coverage should increase. In Medicare, sometimes a Prior-authorization is a little bit of a hassle, but they get approved. 1 out of 5 of our patients are on Medicare today and Medicare is about 30%, so we are about average.
If you have COPD, history of Asthma, or if you smoke, you’re not the right candidate for this product. In the studies they did, they do not see a significant impact on lung capacity with using Afrezza.
What’s coming down the pike for Mannkind?
• We’ll continue to see more insurance coverage and people’s co-pays getting lower.
• We just launched a titration box (4&8, and 4, 8 & 12 cartridges).
• We’re cosponsoring a couple TV shows. One will be airing on Discovery Life Channel in the Summer/Fall time-frame.
• Kicking off an initiative with some famous people in the Afro-American community on access to healthcare, encouraging people to seek treatment.
• MNKD as a company is continuing to innovate their business model to be a solution to diabetes care, so we’re thinking about what are the gaps in the marketplace that we can fulfill. We’re looking to be a different kind of company. When you have the doctor, patient, payer and pharmaceutical company all working together to achieve a common goal, you will probably be more successful. There are multiple problems like the patient can’t get access to the drug, or you can’t get in to the doctor, you can’t get coverage for the drug. That’s the problems that people face: there’s multiple co-pays, multiple struggles just to get access to your healthcare, but let’s try to find ways to streamline that and make that easier. That’s one of our core missions that we’re looking at. How do we make it Uber-like - as easy, smooth and flawless execution as Uber. I hope that one day we can get people’s health care to be that easy. From the time you get diagnosed, to treatment, to refills to health records. I think over the next 12-36 months we’re going to be able to see a nice improvement in making people’s lives easier and hopefully less hassle at the end of the day.
|
|
|
|
Post by sportsrancho on Mar 10, 2017 21:10:51 GMT -5
Good interview. Thanks for posting that, Sports. In case you don't have a spare 30 minutes to listen to that, here are the highlights that stood out to me: Mike thinks that over the next 12 to 18 months, people’s lives are going to get a lot better (less finger pricks, etc.). You will see more inhalable insulin – it will be more mainstream, oral tablets, once-daily injections, once-weekly injections. People’s lives with diabetes will start to get a lot better. Shows like this help us get the word out that Afrezza is still available. It's not going anywhere. If you were on Afrezza, it's easy to get back on it. Medicare coverage isn’t as strong as Commercial. Commercially, we have a little over 70% coverage. With Medicare, sometimes you might need a minor prior-authorization, which isn’t a big deal. We usually get those approved in a day or two. It takes about 18 months to get a medicare plan added. More than half medicare plans aren’t covered, but as we get to 2018 that coverage should increase. In Medicare, sometimes a Prior-authorization is a little bit of a hassle, but they get approved. 1 out of 5 of our patients are on Medicare today and Medicare is about 30%, so we are about average. If you have COPD, history of Asthma, or if you smoke, you’re not the right candidate for this product. In the studies they did, they do not see a significant impact on lung capacity with using Afrezza. What’s coming down the pike for Mannkind? • We’ll continue to see more insurance coverage and people’s co-pays getting lower. • We just launched a titration box (4&8, and 4, 8 & 12 cartridges). • We’re cosponsoring a couple TV shows. One will be airing on Discovery Life Channel in the Summer/Fall time-frame. • Kicking off an initiative with some famous people in the Afro-American community on access to healthcare, encouraging people to seek treatment. • MNKD as a company is continuing to innovate their business model to be a solution to diabetes care, so we’re thinking about what are the gaps in the marketplace that we can fulfill. We’re looking to be a different kind of company. When you have the doctor, patient, payer and pharmaceutical company all working together to achieve a common goal, you will probably be more successful. There are multiple problems like the patient can’t get access to the drug, or you can’t get in to the doctor, you can’t get coverage for the drug. That’s the problems that people face: there’s multiple co-pays, multiple struggles just to get access to your healthcare, but let’s try to find ways to streamline that and make that easier. That’s one of our core missions that we’re looking at. How do we make it Uber-like - as easy, smooth and flawless execution as Uber. I hope that one day we can get people’s health care to be that easy. From the time you get diagnosed, to treatment, to refills to health records. I think over the next 12-36 months we’re going to be able to see a nice improvement in making people’s lives easier and hopefully less hassle at the end of the day. I don't know how you do that but it's awesome thanks:-) Just FWI. A doctor just followed me on Twitter. He's been on the Biggest Loser. I think we are getting attention because of Reversed: |
|
|
|
Post by dreamboatcruise on Mar 10, 2017 21:28:44 GMT -5
Good interview. Thanks for posting that, Sports. In case you don't have a spare 30 minutes to listen to that, here are the highlights that stood out to me: Mike thinks that over the next 12 to 18 months, people’s lives are going to get a lot better (less finger pricks, etc.). You will see more inhalable insulin – it will be more mainstream, oral tablets, once-daily injections, once-weekly injections. People’s lives with diabetes will start to get a lot better. Shows like this help us get the word out that Afrezza is still available. It's not going anywhere. If you were on Afrezza, it's easy to get back on it. Medicare coverage isn’t as strong as Commercial. Commercially, we have a little over 70% coverage. With Medicare, sometimes you might need a minor prior-authorization, which isn’t a big deal. We usually get those approved in a day or two. It takes about 18 months to get a medicare plan added. More than half medicare plans aren’t covered, but as we get to 2018 that coverage should increase. In Medicare, sometimes a Prior-authorization is a little bit of a hassle, but they get approved. 1 out of 5 of our patients are on Medicare today and Medicare is about 30%, so we are about average. If you have COPD, history of Asthma, or if you smoke, you’re not the right candidate for this product. In the studies they did, they do not see a significant impact on lung capacity with using Afrezza. What’s coming down the pike for Mannkind? • We’ll continue to see more insurance coverage and people’s co-pays getting lower. • We just launched a titration box (4&8, and 4, 8 & 12 cartridges). • We’re cosponsoring a couple TV shows. One will be airing on Discovery Life Channel in the Summer/Fall time-frame. • Kicking off an initiative with some famous people in the Afro-American community on access to healthcare, encouraging people to seek treatment. • MNKD as a company is continuing to innovate their business model to be a solution to diabetes care, so we’re thinking about what are the gaps in the marketplace that we can fulfill. We’re looking to be a different kind of company. When you have the doctor, patient, payer and pharmaceutical company all working together to achieve a common goal, you will probably be more successful. There are multiple problems like the patient can’t get access to the drug, or you can’t get in to the doctor, you can’t get coverage for the drug. That’s the problems that people face: there’s multiple co-pays, multiple struggles just to get access to your healthcare, but let’s try to find ways to streamline that and make that easier. That’s one of our core missions that we’re looking at. How do we make it Uber-like - as easy, smooth and flawless execution as Uber. I hope that one day we can get people’s health care to be that easy. From the time you get diagnosed, to treatment, to refills to health records. I think over the next 12-36 months we’re going to be able to see a nice improvement in making people’s lives easier and hopefully less hassle at the end of the day. Just a slight correction. I think the first comment should be about commercial insurance plans with PA requirement. |
|
|
|
Post by kc on Mar 10, 2017 21:45:41 GMT -5
Great interview but they use a crappy old picture. I sent a message to Mike to see if they could get that changed. Not his fault but they should send publications new current Technosphe photos. They fixed the image today. Glad MannKind had sway to gat that accomplished. |
|
|
|
Post by gamblerjag on Mar 10, 2017 23:11:07 GMT -5
This came out today. In no way am I suggesting that NOVO buying MNKD is likely. but seeing the aquiring in the single billion $$$ would be plausible of MNKD's worth in the next 2 years. and you know what.. I'd take it!! have a great weekend all. pharmaphorum.com/news/novo-looking-ma-revive-fortunes-new-ceo/#This represents a change in strategy, as former CEO Lars Rebien Sorensen had avoided M&A in favour of developing the company’s insulin business, and marketing the highly successful GLP-1 blood sugar drug, Victoza (liraglutide). But the company suffered an R&D setback late last year when it shelved development of an insulin pill that could have revolutionised diabetes treatment by ending the need for constant injections. Novo said the costs associated with manufacturing the treatment would have been prohibitive. But an even greater drag on growth is the increasingly aggressive price-discounting and exclusion of certain drugs from approved lists employed by US health insurers. Although Jorgensen would not comment on rumours of talks with US blood disorder biotech Global Blood Therapeutics, he did say that blood products is an area of interest for his firm. Much of the company’s business is centred on diabetes, but Jorgensen is looking for “bolt on” deals that could add to its offering in other areas. “In my view we should do smaller deals, low single-digit billions of dollars,” said Jorgensen.
With increased competition from a biosimilar of Sanofi’s big-selling insulin Lantus squeezing prices in the US, Novo has warned that profits might slip in 2017, after years of growth that has seen the company transform itself into one of the world’s top pharmas. But Novo already markets treatments in haemophilia and obesity – so buying companies with products or exciting research in these fields would make sense. Jorgensen added: “It is not my ambition to go out and do deals where we would not be bringing significant value in terms of disease understanding, commercial infrastructure or manufacturing. The more of those boxes you can tick the better.” |
|
|
|
Post by slugworth008 on Mar 11, 2017 0:10:57 GMT -5
This came out today. In no way am I suggesting that NOVO buying MNKD is likely. but seeing the aquiring in the single billion $$$ would be plausible of MNKD's worth in the next 2 years. and you know what.. I'd take it!! have a great weekend all. pharmaphorum.com/news/novo-looking-ma-revive-fortunes-new-ceo/#This represents a change in strategy, as former CEO Lars Rebien Sorensen had avoided M&A in favour of developing the company’s insulin business, and marketing the highly successful GLP-1 blood sugar drug, Victoza (liraglutide). But the company suffered an R&D setback late last year when it shelved development of an insulin pill that could have revolutionised diabetes treatment by ending the need for constant injections. Novo said the costs associated with manufacturing the treatment would have been prohibitive. But an even greater drag on growth is the increasingly aggressive price-discounting and exclusion of certain drugs from approved lists employed by US health insurers. Although Jorgensen would not comment on rumours of talks with US blood disorder biotech Global Blood Therapeutics, he did say that blood products is an area of interest for his firm. Much of the company’s business is centred on diabetes, but Jorgensen is looking for “bolt on” deals that could add to its offering in other areas. “In my view we should do smaller deals, low single-digit billions of dollars,” said Jorgensen.
With increased competition from a biosimilar of Sanofi’s big-selling insulin Lantus squeezing prices in the US, Novo has warned that profits might slip in 2017, after years of growth that has seen the company transform itself into one of the world’s top pharmas. But Novo already markets treatments in haemophilia and obesity – so buying companies with products or exciting research in these fields would make sense. Jorgensen added: “It is not my ambition to go out and do deals where we would not be bringing significant value in terms of disease understanding, commercial infrastructure or manufacturing. The more of those boxes you can tick the better.” I'd take that in a heartbeat - |
|
